Market Research Logo

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Skin And Soft Tissue Infections - Pipeline Review, H1 2015’, provides an overview of the Skin And Soft Tissue Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Skin And Soft Tissue Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Skin And Soft Tissue Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Skin And Soft Tissue Infections Overview
Therapeutics Development
Pipeline Products for Skin And Soft Tissue Infections - Overview
Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis
Skin And Soft Tissue Infections - Therapeutics under Development by Companies
Skin And Soft Tissue Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Skin And Soft Tissue Infections - Products under Development by Companies
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development
Allergan Plc
Atox Bio Inc.
Cempra, Inc.
CorMedix, Inc.
CrystalGenomics, Inc.
Debiopharm International S.A.
Dong-A Socio Group
GlaxoSmithKline Plc
Melinta Therapeutics, Inc
MicuRx Pharmaceuticals, Inc.
Motif Bio Plc
Nabriva Therapeutics AG
NovaDigm Therapeutics, Inc.
Phosphagenics Limited
Takeda Pharmaceutical Company Limited
Tetraphase Pharmaceuticals Inc.
The Medicines Company
Wockhardt Limited
Skin And Soft Tissue Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acorafloxacin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-7013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CG-400549 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRMD-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debio-1450 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debio-1452 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eravacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fusidic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gepotidacin mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iclaprim mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IOG-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KBP-7072 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lefamulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NDV-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oritavancin diphosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radezolid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siderocillin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Skin Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WCK-2349 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Skin And Soft Tissue Infections - Recent Pipeline Updates
Skin And Soft Tissue Infections - Dormant Projects
Skin And Soft Tissue Infections - Discontinued Products
Skin And Soft Tissue Infections - Product Development Milestones
Featured News & Press Releases
Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
Aug 05, 2014: Cubist’s Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations
Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist’s SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections
Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
Sep 10, 2012: Atox Bio’s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections
May 05, 2011: Furiex To Present Two Abstracts Featuring JNJ-Q2 At Joint Meeting Of ECCMID And ICC
Oct 15, 2010: Cempra To Present New Data On TAKSTA At Annual Meeting Of Infectious Diseases Society Of America
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Skin And Soft Tissue Infections, H1 2015
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Skin And Soft Tissue Infections - Pipeline by Allergan Plc, H1 2015
Skin And Soft Tissue Infections - Pipeline by Atox Bio Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Cempra, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by CorMedix, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by CrystalGenomics, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Debiopharm International S.A., H1 2015
Skin And Soft Tissue Infections - Pipeline by Dong-A Socio Group, H1 2015
Skin And Soft Tissue Infections - Pipeline by GlaxoSmithKline Plc, H1 2015
Skin And Soft Tissue Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Skin And Soft Tissue Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Motif Bio Plc, H1 2015
Skin And Soft Tissue Infections - Pipeline by Nabriva Therapeutics AG, H1 2015
Skin And Soft Tissue Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Phosphagenics Limited, H1 2015
Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Skin And Soft Tissue Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by The Medicines Company, H1 2015
Skin And Soft Tissue Infections - Pipeline by Wockhardt Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Skin And Soft Tissue Infections Therapeutics - Recent Pipeline Updates, H1 2015
Skin And Soft Tissue Infections - Dormant Projects, H1 2015
Skin And Soft Tissue Infections - Dormant Projects (Contd..1), H1 2015
Skin And Soft Tissue Infections - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Skin And Soft Tissue Infections, H1 2015
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report